The Phase III trial AV001 aims to evaluate QUTENZA in post-surgical neuropathic pain (PSNP), a debilitating complication of surgery occurring after approximately 10 percent of all surgical procedures ...
- The Phase III trial AV001 aims to evaluate QUTENZA® in post-surgical neuropathic pain (PSNP), a debilitating complication of surgery occurring after approximately 10 percent of all surgical ...
Report on how AI is redefining market landscape - The global gastroparesis drugs market size is estimated to grow by USD 1.42 billion from 2024-2028, according to Technavio. The market is estimated ...